TNF and tuberculosis: Furthermore, in the context of infections such as tuberculosis (a major risk of treatment with anti‐TNF), the main driver of cartilage degradation is MMP‐9, with low secreted levels of MMP‐1 (100‐fold lower than in RA SF) 42, 43.